ROVI obtains second place in a global sustainability rating

ROVI has obtained second place among 360 international pharmaceutical companies in the sustainability rating drawn up by Sustainalytics, a global leader in the evaluation of the Corporate Social Responsibility and Corporate Governance


ROVI participated voluntarily in this rating, which measures the sustainability of companies based on criteria such as corporate governance, business ethics, product management, bribery and corruption and human capital, among others. Thus, the ESG (Environmental, Social and Governance) rating is calculated and furnishes the basis for the company ratings.

In this rating, ROVI obtained the second best rating in the pharmaceutical company category and the 30th of a total of 750 companies in the sector, which includes biotechnology companies and pharmaceutical and health equipment laboratories.

We are proud to see that the management of ROVI, a day-to-day reflection of the company’s values, has received such a high sustainability rating.

No votes yet
 
Relacionados
Al cierre del primer trimestre de 2023 ROVI LOGRA UNOS INGRESOS DE 201,9 MILLONES DE EUROS EN EL PRIMER TRIMESTRE POSPANDEMIA La...
15 min
10/05/2023
ROVI INICIA EL DESARROLLO CLÍNICO DE UNA NUEVA FORMULACIÓN TRIMESTRAL DE LETROZOL (LETROZOL LEBE) El objetivo de la nueva...
7 min
25/04/2023
Madrid, 12 de abril de 2023 La Universidad Pontificia Comillas, en colaboración con Laboratorios Farmacéuticos ROVI, ha puesto en marcha...
3 min
12/04/2023